Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension

By afschroeder • November 17, 2025

McLaughlin VV, Howard L, Elwing J, Fernandes CC, Gaine S, Galiè N, Oudiz RJ, Stefani M, Stickel S, Strachan P, Tamura Y, Kim NH. Evaluating oral selexipag in PAH: Insights on survival, safety and dosing patterns from the complete observation period of GRIPHON and its open-label extension. J Heart Lung Transplant. 2025 Nov 14:S1053-2498(25)02393-9. doi: 10.1016/j.healun.2025.11.007. Epub ahead of print. PMID: 41242357.

Tags: Cardiology/Epi, Harbor UCLA, Long-term safety, long-term survival, open-label extension, Publications, pulmonary arterial hypertension, Selexipag

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]

Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population

Spencer-Bonilla G, Fan J, Cheng P, Din N, Rodriguez F, Davies M, Papas MA, Huang J, Venditto J, Witteles RM, Heidenreich P, Alexander K, Sandhu[...]